Cholera Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, Others), By Application (Hospitals & Clinics, Research & Academic Laboratories, Others), Regional Insights and Forecast to 2035
Cholera Vaccine Market Overview
The global Cholera Vaccine Market size estimated at USD 123.93 million in 2026 and is projected to reach USD 340.3 million by 2035, growing at a CAGR of 11.88% from 2026 to 2035.
The global cholera vaccine market is experiencing renewed public health demand as recurring outbreaks, humanitarian emergencies, and preventive immunization programs increase requirements for reliable oral vaccines. In 2025, 47 countries reported 451,499 cholera cases and 7,870 deaths, demonstrating the continued importance of accessible immunization alongside safe drinking water and effective sanitation. Vaccine procurement increasingly emphasizes manufacturing capacity, emergency stockpile availability, cold-chain reliability, and equitable distribution. Improvements in oral vaccine production have also enabled preventive campaigns to resume during 2026, creating opportunities for suppliers supporting both outbreak response and longer-term disease prevention. However, demand remains strongly influenced by public health financing, disease surveillance, and coordinated international vaccination programs.
The USA cholera vaccine market primarily serves international travelers, specialized healthcare providers, and selected research institutions rather than widespread domestic immunization campaigns. Vaxchora has been authorized in the United States for eligible travelers aged 2 through 64 years visiting areas with active cholera transmission. Demand is concentrated within travel medicine clinics and healthcare facilities providing destination-specific preventive services. Medical recommendations, international travel patterns, and changing outbreak conditions influence vaccine utilization. The domestic market also benefits from established regulatory oversight, clinical research infrastructure, and professional vaccination networks. However, relatively limited local cholera transmission means demand differs substantially from countries experiencing recurring outbreaks and requiring large-scale community vaccination campaigns.
Key Findings
- Market Driver: Persistent cholera transmission remains the principal demand driver, with 47 countries reporting cholera cases during 2025, increasing the importance of emergency vaccine procurement and preventive immunization programs.
- Major Market Restraint: Supply concentration remains a structural concern because 1 manufacturer, Eubiologics, was identified as producing oral cholera vaccines at the scale required for international mass vaccination campaigns.
- Emerging Trends: Preventive vaccination is returning to national immunization strategies, supported by an initial 20 million doses allocated during February 2026 to priority countries experiencing significant cholera risks.
- Regional Leadership: Asia-Pacific remains strategically important for oral vaccine production and preventive procurement, while the African and Eastern Mediterranean regions together accounted for 93% of reported cholera cases in 2025.
- Competitive Landscape: Eubiologics Co., Ltd. is a significant manufacturer supporting emergency vaccination programs, with global oral cholera vaccine supply reaching nearly 70 million doses during 2025.
- Market Segmentation: Euvichol & Euvichol-Plus are prominent in mass vaccination procurement, while Hospitals & Clinics remain central to administration; verified percentage market shares for these 2 segments are unavailable.
- Recent Development: During February 2026, vaccine supply improvements supported the allocation of 20 million oral cholera vaccine doses for renewed preventive immunization campaigns.
Latest Trends
The cholera vaccine market is shifting toward a combination of emergency outbreak response and preventive immunization in vulnerable communities. During February 2026, an initial 20 million doses were allocated for preventive vaccination campaigns in Mozambique, Bangladesh, and the Democratic Republic of the Congo. This development reflects renewed confidence in vaccine availability following prolonged international supply shortages. Governments and immunization partners are increasingly integrating vaccination planning with disease surveillance, emergency preparedness, community engagement, and sanitation improvements. Another important market trend involves simplified oral vaccine formulations and improvements in manufacturing scalability. Euvichol-S received international prequalification in 2024, supporting efforts to improve production efficiency and expand vaccine availability. Simplified formulations can reduce operational complexity while maintaining necessary safety and quality requirements. Manufacturers are also emphasizing production consistency, packaging improvements, and practical distribution systems. These changes are particularly relevant for humanitarian operations where large populations require timely vaccination despite transportation challenges and constrained healthcare infrastructure.
Market Dynamics
Driver
"Recurring cholera outbreaks accelerate demand for accessible preventive vaccination."
Persistent cholera transmission remains a fundamental driver of vaccine procurement worldwide. Global surveillance identified 451,499 reported cholera cases during 2025, emphasizing the continuing disease burden in vulnerable communities. Outbreaks frequently emerge in locations experiencing inadequate sanitation, population displacement, extreme weather, and restricted access to medical treatment. These conditions encourage health authorities to maintain vaccine preparedness and strengthen community-level immunization arrangements. Emergency procurement organizations consequently prioritize dependable manufacturing partnerships and the ability to distribute vaccines rapidly when transmission increases. Preventive vaccination is becoming more important as vaccine availability improves and governments seek alternatives to repeated emergency interventions. Global oral cholera vaccine supply approached 70 million doses in 2025, representing substantial improvement compared with earlier shortages. More dependable availability allows public health organizations to plan vaccination in vulnerable areas before outbreaks intensify. This transition supports sustained manufacturer engagement, longer procurement horizons, and stronger integration between immunization services and broader infectious disease prevention programs.
Restraint
"Concentrated manufacturing capacity restricts flexibility in global vaccine procurement."
The cholera vaccine industry continues to face challenges arising from limited large-scale production capacity and uneven geographic access. In February 2026, international health authorities identified 1 manufacturer supplying oral cholera vaccines at the scale needed for mass vaccination campaigns. Dependence on concentrated production creates exposure to manufacturing interruptions, regulatory delays, raw-material constraints, and unexpected demand increases. Procurement agencies must consequently manage allocation decisions carefully, particularly when several countries experience outbreaks simultaneously or humanitarian emergencies disrupt established distribution arrangements. Financial and infrastructure constraints also limit vaccination accessibility in affected communities. Vaccine products generally require controlled storage conditions, with many oral cholera vaccines distributed within a temperature range of 2–8°C. Maintaining these conditions can be difficult in remote settlements, disaster-affected communities, and healthcare facilities with inconsistent electricity supplies. Transportation expenses, inadequate staffing, weak disease surveillance, and limited local budgets further complicate vaccination programs. Such operational challenges can delay immunization even when vaccine doses are available internationally.
Opportunity
Expansion of preventive immunization creates opportunities for scalable vaccine manufacturing.
The resumption of preventive vaccination represents an important opportunity for manufacturers and public health procurement partners. During February 2026, Mozambique received an allocation of 3.6 million doses as preventive campaigns restarted after several years of constrained vaccine availability. This shift encourages broader planning beyond immediate outbreak containment and creates demand for dependable production schedules. Manufacturers capable of maintaining international quality standards and supplying affordable vaccines may benefit from longer-term procurement arrangements and expanding immunization requirements across high-risk populations. Technology development offers additional opportunities through simplified formulations, improved presentation formats, and production efficiency. The international prequalification of Euvichol-S in 2024 demonstrated progress toward simplifying established oral cholera vaccine manufacturing. Continued investment in manufacturing systems, analytical testing, and packaging optimization could increase the number of usable doses available for public health campaigns. Partnerships between established vaccine companies, research institutions, and regional manufacturers may also strengthen supply diversification and improve resilience against future disease emergencies.
Challenge
Unpredictable outbreaks complicate vaccination forecasting and distribution planning.
Accurately predicting cholera vaccine requirements remains difficult because outbreaks respond rapidly to environmental conditions, population displacement, and humanitarian disruptions. Reported cholera deaths increased by approximately 30% in 2025 compared with the preceding year, despite a decline in reported cases. This divergence highlights the importance of timely medical access and effective prevention programs. Manufacturers and procurement organizations must balance immediate outbreak requirements against preventive commitments while ensuring sufficient stockpile availability for unexpected emergencies. Another challenge involves coordinating vaccination with clinical treatment, safe water access, sanitation, and community engagement. Two-dose oral cholera vaccine regimens provide longer-lasting protection, while single-dose strategies have been used extensively during periods of constrained supply. Health authorities must consider disease risk, vaccine availability, operational feasibility, and population movement when selecting vaccination strategies. Maintaining accurate vaccination records and achieving equitable access in geographically isolated communities remain significant implementation difficulties.
Segmentation Analysis
By Types
Dukoral: Dukoral represents an established oral cholera vaccine used primarily in travel medicine and selected preventive healthcare settings. Its immunization schedule generally involves 2 doses for adults and older children, with additional age-specific guidance applying to younger eligible recipients. The vaccine contains inactivated cholera bacteria together with a recombinant toxin component and requires administration with a buffer solution. Its commercial position is supported by established regulatory approvals, professional familiarity, and distribution through travel healthcare networks. Demand depends substantially on international travel activity, destination-related health recommendations, and the availability of specialized vaccination services.
Shanchol: Shanchol is an inactivated oral cholera vaccine historically associated with large-scale immunization in endemic communities and humanitarian settings. Its established vaccination approach uses 2 oral doses to provide longer-lasting protection against cholera. The product contributed to earlier public health vaccination initiatives and helped expand access to cholera prevention in resource-constrained settings. However, Shanchol is no longer manufactured, making it important to distinguish historical vaccine utilization from present commercial demand. Its legacy remains relevant when examining changes in vaccine production, procurement diversification, and the transition toward alternative oral formulations.
Vaxchora: Vaxchora is a live attenuated oral cholera vaccine primarily associated with preventive immunization for eligible travelers. The product uses a single-dose administration schedule and is authorized in the United States for individuals aged 2 through 64 years traveling to areas with active cholera transmission. Its market characteristics differ from inactivated formulations used in large community vaccination campaigns. Demand is influenced by travel clinic recommendations, destination risk assessments, product availability, and regulatory requirements. Specialized healthcare professionals play an important role in vaccine administration and traveler counseling. Its global commercial market share remains insufficiently documented for reliable numerical reporting.
Euvichol & Euvichol-Plus: Euvichol and Euvichol-Plus are important oral cholera vaccine products supporting public health vaccination activities. Eubiologics contributed to global vaccine availability approaching 70 million doses during 2025 across international supply arrangements. These formulations are particularly relevant for outbreak response and preventive campaigns in vulnerable populations. Their deployment is supported by international procurement mechanisms, public health partnerships, and established experience in mass vaccination settings. Simplified related formulations have strengthened manufacturing flexibility and vaccine availability. Euvichol products occupy a prominent position in the international mass vaccination segment, although a validated percentage share of the total commercial market is unavailable.
Others: The Others category covers additional cholera vaccine presentations and development-stage approaches not included within the specifically named product groups. Vaccine development generally requires extensive clinical evaluation, manufacturing validation, and regulatory review before commercial distribution. Emerging approaches may explore improved immune responses, simplified dosage schedules, alternative formulations, and more practical administration requirements. Research activity also contributes to understanding protection across different patient populations and epidemiological settings. Prospective products face significant development expenses and uncertain commercialization timelines.
By Applications
Hospitals & Clinics: Hospitals and clinics provide essential infrastructure for administering oral cholera vaccines, counseling travelers, and coordinating preventive immunization activities. The resumption of preventive campaigns in 2026 increased the importance of organized healthcare delivery networks and community vaccination teams. Healthcare facilities support patient eligibility assessment, vaccine preparation, adverse-event monitoring, and integration with broader infectious disease prevention services. Specialized travel clinics serve individuals visiting countries where cholera transmission is active, while hospitals in vulnerable communities contribute to emergency preparedness and outbreak response. This application represents a major practical delivery channel, although an independently verified global market-share percentage is unavailable.
Research & Academic Laboratories: Research and academic laboratories support vaccine innovation through microbiological investigations, immunogenicity studies, clinical research, and analytical testing. Research involving 2-dose immunization schedules continues to inform assessments of protection duration and differences between vaccination approaches. Academic institutions also evaluate disease transmission, immune responses, vaccine effectiveness, and potential improvements in formulation technology. Laboratory activities contribute to regulatory evidence development and manufacturing quality assessment rather than representing the primary destination for population-level vaccine administration. Demand within this application is linked to research funding, clinical development programs, and collaborations between manufacturers and scientific organizations.
Others: Other applications include humanitarian vaccination programs, community outreach activities, international immunization partnerships, and specialized public health delivery arrangements operating beyond conventional clinical settings. During February 2026, 20 million oral cholera vaccine doses were allocated for preventive programs in priority countries. These activities frequently involve mobile vaccination teams, temporary healthcare facilities, community health workers, and coordinated emergency distribution systems. Their importance increases during floods, displacement emergencies, and outbreaks affecting communities with limited access to conventional medical infrastructure. Separating this category from hospital-led vaccination requires detailed procurement and administration records that are not consistently available internationally.
Regional Outlook
North America
North America represents an established cholera vaccine market driven primarily by international travel immunization, specialized healthcare services, vaccine research, and regulatory oversight. In the United States, Vaxchora is approved for eligible individuals aged 2 through 64 years traveling to areas with active cholera transmission, supporting demand through travel medicine clinics and healthcare providers. The region benefits from advanced pharmaceutical infrastructure, established vaccine distribution systems, and awareness of travel-related infectious disease risks. Although domestic cholera transmission is relatively uncommon, international travel to vulnerable destinations sustains demand for preventive vaccination and professional medical counseling. Hospitals, specialized clinics, and research institutions contribute to regional market activity through vaccine administration, clinical assessments, and immunization research. Canada also supports travel-related vaccination through regulated healthcare channels and established preventive medicine practices. Increasing international mobility, destination-specific vaccination recommendations, and continuing development of infectious disease preparedness strategies are expected to support regional market opportunities.
Europe
Europe maintains an important position in the cholera vaccine market through advanced healthcare infrastructure, established travel vaccination services, and strong pharmaceutical research capabilities. Dukoral remains an established oral cholera vaccine within relevant European markets, with the conventional primary vaccination schedule for adults generally involving 2 doses. Regional demand is influenced by international travel to cholera-affected countries, professional vaccination recommendations, and preventive healthcare awareness. Countries including Germany, France, the United Kingdom, and Sweden maintain specialized travel medicine services that support vaccination access for eligible travelers. European healthcare organizations also contribute to international infectious disease surveillance, humanitarian vaccination financing, and the evaluation of vaccine safety and effectiveness. Research institutions and regulatory agencies play an important role in maintaining vaccine quality standards and supporting clinical development. Although widespread domestic cholera vaccination is generally unnecessary, changing international outbreak patterns can influence traveler demand and procurement planning. Continued participation in humanitarian immunization initiatives and international vaccine partnerships strengthens Europe's strategic importance within the broader cholera vaccine industry.
Asia-Pacific
Asia-Pacific occupies a strategically important position in the cholera vaccine market because of its manufacturing capabilities, large population base, established disease prevention programs, and continuing exposure to waterborne infectious diseases. Bangladesh was allocated 10.3 million oral cholera vaccine doses under preventive vaccination arrangements announced in February 2026, demonstrating substantial regional demand for immunization preparedness. Countries including Bangladesh, India, and other vulnerable Asian markets face cholera risks associated with population density, seasonal flooding, sanitation inequalities, and limited access to safe drinking water in certain communities. South Korea contributes significantly to international vaccine availability through Eubiologics, whose oral cholera vaccine manufacturing operations support global public health procurement. Regional governments and healthcare organizations increasingly recognize the importance of integrating immunization with disease surveillance, sanitation improvements, and community health initiatives. Hospitals, public vaccination centers, and humanitarian healthcare teams support vaccine distribution across urban settlements and remote communities. Manufacturing innovation, growing public health investment, and renewed preventive immunization campaigns are expected to strengthen the region's long-term market significance.
Middle East and Africa
The Middle East and Africa represent one of the most important regions for cholera vaccine deployment because recurrent outbreaks, humanitarian emergencies, infrastructure damage, and unequal access to clean water create substantial vaccination requirements. The African and Eastern Mediterranean WHO regions together accounted for approximately 93% of reported global cholera cases during 2025, highlighting the concentration of disease burden across vulnerable communities. Countries including the Democratic Republic of the Congo, Mozambique, Nigeria, Sudan, South Sudan, and Yemen face recurring challenges involving population displacement, healthcare access, sanitation infrastructure, and disease surveillance. In February 2026, preventive vaccination allocations included 6.1 million doses for the Democratic Republic of the Congo and 3.6 million doses for Mozambique, strengthening outbreak prevention efforts. Regional immunization programs frequently depend on international vaccine procurement, humanitarian partnerships, mobile vaccination teams, and coordinated emergency response operations. Continued public health investment is essential for improving vaccine accessibility, expanding cold-chain infrastructure, and supporting community vaccination coverage.
Rest of the World
The Rest of the World category includes Latin America, the Caribbean, and other markets requiring cholera vaccines for targeted public health interventions, travel-related prevention, and emergency preparedness. Globally, 47 countries reported cholera cases during 2025, emphasizing the continuing international distribution of disease risks and the need for adaptable vaccination strategies. In Latin America and the Caribbean, vulnerable communities may face heightened cholera risks when natural disasters, population displacement, damaged sanitation systems, or inadequate access to safe drinking water disrupt public health conditions. Haiti remains an important example of a market where cholera control requires coordinated medical services, epidemiological surveillance, and community-level preventive measures. Vaccine procurement in these markets is influenced by outbreak severity, healthcare infrastructure, public health financing, and international humanitarian assistance. Hospitals, community vaccination teams, and regional health organizations support immunization activities when disease transmission threatens vulnerable populations. Expanding disease surveillance capabilities, improving emergency stockpile access, and strengthening collaboration with international vaccination partners will remain important for regional market development.
List of Top Cholera Vaccine Companies
- Astellas Pharma, Inc.
- Celldex Therapeutics, Inc.
- Emergent BioSolutions, Inc. (PaxVax, Inc.)
- Eubiologics Co., Ltd.
- Johnson & Johnson (Crucell)
- Sanofi (Shantha Biotechnics Private Limited)
Top Two Companies with Highest Market Share
- Eubiologics Co., Ltd.: Eubiologics is the leading identifiable large-scale supplier within international oral cholera vaccine campaigns, although its precise worldwide commercial market-share percentage has not been independently verified.
- Emergent BioSolutions, Inc. (PaxVax, Inc.): The company's historical association with Vaxchora makes it relevant to the specialized travel vaccination segment, but its current global cholera vaccine market-share ranking and percentage remain unverified.
Investment Analysis and Opportunities
Investment activity within the cholera vaccine industry is increasingly influenced by manufacturing resilience, international procurement requirements, and renewed emphasis on preventive immunization. Global oral cholera vaccine availability increased from approximately 35 million doses in 2022 to nearly 70 million doses during 2025, highlighting the potential impact of sustained production investment. Manufacturing expansion requires specialized facilities, validated production processes, reliable raw-material supplies, and effective quality-control systems. Investment opportunities also exist in improving batch consistency, simplifying manufacturing workflows, and increasing production flexibility. Public health procurement partnerships can provide greater demand visibility, although manufacturers must carefully assess regulatory requirements and the unpredictability of future outbreak patterns. Additional investment opportunities arise from vaccine delivery infrastructure, cold-chain management, community vaccination coordination, and development of alternative manufacturing capacity. An initial allocation of 20 million doses for preventive campaigns in February 2026 demonstrated the scale of coordinated international vaccination requirements. Companies developing efficient storage systems, vaccine packaging, distribution technology, and analytical manufacturing services may benefit from broader supply-chain modernization.
New Product Development
New product development in the cholera vaccine industry increasingly focuses on manufacturing simplification, practical administration, and dependable protection across vulnerable populations. Euvichol-S achieved international prequalification in 2024, representing an important development in simplified oral vaccine manufacturing. This product evolution supports efforts to improve production efficiency while maintaining essential quality and immunization requirements. Research organizations continue investigating vaccine effectiveness, immune response durability, and suitable immunization approaches for different epidemiological conditions. Manufacturers must demonstrate adequate product consistency, safety, and clinical performance before introducing major formulation changes. Improvements in packaging and distribution can also support vaccination programs operating in resource-constrained environments. Product development also reflects differences between traveler-focused vaccination and large-scale community immunization. Vaxchora uses a single-dose approach for eligible travelers, whereas established inactivated oral cholera vaccine schedules commonly involve 2 doses for longer-lasting protection. These differences influence formulation design, regulatory pathways, healthcare delivery requirements, and commercial positioning.
Five Recent Developments
- February 2026 – Eubiologics Co., Ltd. – Expanded Supply Supports Preventive Vaccination Restart: International health authorities acknowledged Eubiologics' contribution to expanded oral cholera vaccine availability as preventive vaccination resumed, supported by an initial allocation of 20 million doses across priority countries.
- 2026 – Emergent BioSolutions, Inc. (PaxVax, Inc.) – Historical Cholera Vaccine Portfolio Assessment: Vaxchora remains relevant to the history of specialized traveler vaccination, but a distinct cholera vaccine product launch or manufacturing expansion by this company during 2026 could not be verified.
- 2026 – Sanofi (Shantha Biotechnics Private Limited) – Established Vaccine Program Status Review: Shanchol remains important to the historical development of oral cholera immunization, although its production has ceased and no new company-specific cholera vaccine launch during 2026 could be verified.
- 2026 – Johnson & Johnson (Crucell) – Historical Vaccine Business Position Review: The company's historical vaccine activities contribute context to industry development, but no independently confirmed cholera vaccine commercialization or manufacturing milestone during 2026 was established.
- 2026 – Astellas Pharma, Inc. – Cholera Vaccine Activity Verification Review: No independently confirmed company-specific cholera vaccine approval, product launch, or commercial expansion during 2026 was identified, preventing a factual development announcement from being reported.
Future Outlook
The future of the cholera vaccine market will depend on sustained manufacturing capacity, expanded preventive immunization, and stronger international coordination between vaccine suppliers and public health organizations. Improving the reliability of vaccine availability could allow governments to develop more consistent prevention strategies rather than relying primarily on emergency responses after outbreaks begin. Manufacturers offering efficient production, dependable quality, and practical vaccine presentation formats are likely to remain important partners in international disease prevention. Emerging manufacturing capabilities and diversified procurement arrangements could strengthen global supply resilience while improving access for communities experiencing repeated cholera risks. Continued progress will also require investment in vaccination infrastructure, disease surveillance, healthcare workforce capabilities, and effective community engagement. Vaccine innovation may improve formulation simplicity, distribution efficiency, and program implementation in challenging environments. However, sustainable cholera prevention will continue to depend on combining immunization with access to clean drinking water, sanitation improvements, timely medical treatment, and coordinated public health preparedness.
Cholera Vaccine Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 123.93 Million in 2026 |
|
|
Market Size Value By |
USD 340.3 Million by 2035 |
|
|
Growth Rate |
CAGR of 11.88% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Frequently Asked Questions
The global Cholera Vaccine Market is expected to reach USD 340.3 Million by 2035.
The Cholera Vaccine Market is expected to exhibit a CAGR of 11.88% by 2035.
Astellas Pharma, Inc., Celldex Therapeutics, Inc., Emergent BioSolutions, Inc. (PaxVax, Inc.), Eubiologics Co., Ltd., Johnson & Johnson (Crucell), Sanofi (Shantha Biotechnics Private Limited)
In 2026, the Cholera Vaccine Market is estimated at USD 123.93 Million.